Trial Profile

A pilot study to assess immunogenicity of the prime-boost revaccination strategy using 13-Valent Pneumococcal Conjugate Vaccine followed by 23-Valent Pneumococcal Polysaccharide Vaccine vaccination 8 weeks later in 24 patients with Rheumatoid Arthritis (RA) treated by Methotrexate (MTX) and anti-TNF

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Dec 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 13-valent CRM197 vaccine conjugate (Primary) ; Pneumococcal vaccine (Primary)
Indications Pneumococcal infections
Focus Pharmacodynamics

12 Dec 2017 New trial record
08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com